EODData

MEMBERSHIP REGISTER LOG IN

FRA, 7CA: Camurus AB (publ)

26 Mar 2026
LAST:

40.88

CHANGE:
 0.88		OPEN:
40.88		HIGH:
40.88		ASK:
0.00		VOLUME:
360
CHG(%):
2.11		PREV:
41.76		LOW:
40.88		BID:
0.00		 

CHART

RECENT END OF DAY PRICES

DateOpenHighLowCloseVolume
26 Mar 2640.8840.8840.8840.88360
25 Mar 2640.6041.7640.6041.76360
24 Mar 2641.2041.2041.2041.20100
23 Mar 2640.7840.7840.7840.78100
20 Mar 2642.5242.5242.0042.00100
19 Mar 2642.2642.2642.2642.260
18 Mar 2644.2844.2843.9243.920
17 Mar 2643.2443.6043.2443.600
16 Mar 2643.5443.5443.5443.540
13 Mar 2643.2643.2643.2643.260

PROFILE

Name:Camurus AB (publ)
About:Camurus AB (publ), a biopharmaceutical company, develops and commercializes medicines for severe and chronic diseases in Europe, Africa, the Middle East, North America, and Asia. The company offers Buvidal, a buprenorphine injection for the treatment of opioid dependence and chronic pain; and Brixadi to treat opioid use disorder. It also provides CAM2038 for the treatment of chronic pain; CAM2029, which completed phase III clinical trials for the treatment of acromegaly, and phase III clinical trials to treat gastroenteropancreatic neuroendocrine tumors, as well as in phase II clinical trial to treat polycystic liver diseases; and CAM2043 that is in phase I clinical trial for the treatment of pulmonary arterial hypertension, as well as in Phase II clinical trial to treat Raynaud's phenomenon. In addition, the company is developing CAM2032, which is in phase II clinical trials for the treatment of prostate cancer; CAM4072 that is in phase III clinical trials for the treatment of genetic obesity disorders; CAM2056 that is in phase I clinical trials for the treatment of metabolic diseases; CAM4071, which is in phase I clinical trials for the treatment of endocrine disorder; and CAM2047 that is in phase 1 clinical trial for the treatment of chemotherapy-induced nausea and vomiting. It has strategic partnerships with Braeburn Pharmaceuticals to develop CAM2038 for the treatment of opioid use disorder; and Rhythm Pharmaceuticals Inc. to develop CAM4072 for the treatment of a range of rare genetic disorders of obesity, as well as NewBridge Pharmaceuticals. Camurus AB (publ) was founded in 1991 and is headquartered in Lund, Sweden.
Sector:Healthcare
Industry:Biotechnology
Address:Ideon Science Park, Lund, Sweden, 223 70
Website:https://www.camurus.com
ISIN:SE0007692850
LEI:5493003S6Z6VI7WYFQ06

API SERVICE  NEW

Have you tried our new API Service yet?

For more information, visit our API page.

You can get your ApiKey over HERE.

If you're ready to get going, then jump over to:
https://api.eoddata.com

SYMBOL HISTORY

   Add to Watchlist

DOWNLOAD DATA

Download stock quote history quickly and easily in a variety of formats to suit your needs.

  Download

FUNDAMENTALS

Trailing P/E:46.46 
Forward P/E:21.83 
PEG Ratio:0.21 
Price to Sales:19.31 
Price to Book:0.81 
Profit Margin:0.33 
Operating Margin:0.30 
Return on Assets:0.14 
Return on Equity:0.22 
Revenue:172.89M 
EBITDA:86.55M 
Shares:59.42M 
Market Cap:2.429B 

TECHNICAL INDICATORS

MA5:41.321.1%
MA10:42.323.5%
MA20:43.656.8%
MA50:53.2730.3%
MA100:54.8234.1%
MA200:57.0639.6%
STO9:2.86 
STO14:1.92 
RSI14:33.17 
WPR14:-98.03 
MTM14:-2.54
ROC14:-0.06 
ATR:1.00 
Week High:42.524.0%
Week Low:40.600.7%
Month High:47.4616.1%
Month Low:40.6039.6%
Year High:67.8065.9%
Year Low:40.600.7%
Volatility:77.43